Works as intended!
Epithalon (Epitalon) — clinical & mechanistic profile
Epithalon is a synthetic tetrapeptide (AEDG) that activates telomerase via hTERT upregulation. A September 2025 Biogerontology study confirmed dose-dependent telomere extension in normal epithelial, fibroblast, and cancer cell lines. Brunel University (2025) independently replicated telomere lengthening across cell types. Additional 2025 data shows it restores antioxidant genes (SOD2, catalase, HO-1) and prevents DNA hypomethylation in hyperglycemic retinal cells.
Research status
preclinical
Sequence
Ala-Glu-Asp-Gly
Molecular weight
390.35 Da
Molecular formula
C14H22N4O9
Studied applications
- •Telomerase activation: upregulates hTERT mRNA, activating telomerase during G1 cell cycle phase via TRAP protocol confirmation
- •Telomere elongation: extends telomeres approximately 33.3% in somatic cells, increases proliferative potential beyond Hayflick limit
- •Cell lifespan extension: treated fetal fibroblasts reached 44+ passages vs. 34 for controls
- •Histone H1 binding: binds H1.3 and H1.6 variants, potentially triggering ALT pathways via H19 derepression
- •Anti-tumor effects: reduces spontaneous tumors and metastases in mice; inhibits MMP9 in aging skin fibroblasts
Mechanisms of action
- •hTERT upregulation: increases telomerase catalytic subunit mRNA expression primarily during G1 cell cycle phase
- •Chromatin modification: enters cell nuclei, binds promoter regions (ATTTC motifs) for epigenetic activation
- •Histone H1 binding: binds H1.3 and H1.6 variants, potentially inhibiting telomere stability proteins
- •Cancer cell selectivity: in telomerase-positive cancer cells, may trigger ALT pathway via H19 derepression rather than direct telomerase activation
- •Pineal gland modulation: influences melatonin synthesis pathways; derived from epithalamin (bovine pineal extract)
- •Heterochromatin effects: causes heterochromatin decondensation in elderly lymphocytes
- •Most research originates from a limited number of research groups (primarily Russian)
- •Limited independent replication in Western research institutions
- •No FDA-approved human applications or completed Phase 3 trials
- •Telomerase activation in humans not confirmed in rigorous clinical trials
- •Long-term safety of telomerase activation uncertain (theoretical cancer concerns)
Peer-reviewed references
- Khavinson VK — Epithalamin telomerase activation research (2003)PMID: 12937225View
- Khavinson VK — Peptide bioregulation of aging (2003)PMID: 14501183View
- Anisimov VN — Peptide geroprotector studiesPMID: 16706657View
- Telomere elongation in human somatic cellsPMID: 11524632View
- PMC12411320 — Epithalon histone H1 binding and ALT pathway mechanisms (2024)
For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.
Related products

